Overview
MDCX market data
Price History
MDCX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.05 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.25 – $3.05 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $18.2M · P/B 9.51.
Company News
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) EstimateBenzinga · Aug 12, 2026, 10:02 PM
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with EndometriosisGlobenewswire Inc · Jul 31, 2026, 12:15 PM
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu DhabiBenzinga · Jul 31, 2026, 11:14 AM
EXCLUSIVE: Medicus Pharma Gets UAE Department of Health Approval for Study of Teverelix in Endometriosis; Phase 2a PRECISION-E2 Study Designed to Evaluate Predefined Panel of Genes to Advance Personalized MedicineBenzinga · Jul 31, 2026, 11:14 AM
Medicus Pharma Receives FDA Approval To Proceed With Phase 2b Clinical Study Of SkinJect 200 Mcg To Treat Patients With Gorlin Syndrome Presenting With Multiple Basal Cell CarcinomasBenzinga · Jul 27, 2026, 12:19 PM
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin SyndromeBenzinga · Jul 27, 2026, 12:18 PM
Medicus Pharma shares are trading higher after the company announced that it has received written feedback from the FDA and central Institutional Review Board approval, with modifications, for its optimized Phase 2 clinical study of Teverelix in men following a first episode of acute urinary retention.Benzinga · Jul 16, 2026, 2:56 PM
Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary RetentionBenzinga · Jul 16, 2026, 11:33 AM
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026Benzinga · Jun 22, 2026, 12:05 PM
Medicus Pharma To Present Showcase SkinJect Registrational Strategy, Teverelix Precision Medicine Program At 2026 Bio International ConferenceBenzinga · Jun 22, 2026, 11:40 AM